Calando Pharmaceuticals, Inc. Announces Initial RNAi Product, Goals For 2007; Company To Advance Targeted RNAi Therapeutics Toward The Clinic In Cancer, Further Develop Its Targeted RNAi Delivery Technology

PASADENA, Calif.--(BUSINESS WIRE)--Sept. 6, 2006--Calando Pharmaceuticals Inc., a leading RNAi Therapeutics company and majority-owned subsidiary of Arrowhead Research Corporation (Nasdaq:ARWR), today provided more detail on its product and business goals for 2007.